SEC charges Bristol-Myers Squibb over FCPA violations
Bristol-Myers Squibb will pay the US Securities and Exchange Commission (SEC) US$14 million to settle charges that "its joint venture in China made cash payments and provided other benefits to health care providers at state-owned and state-controlled hospitals in exchange for prescription sales".
To read more
Subscribe to Global Investigations Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Investigations Review experts.